(Q36650726)

15 August 2017

1 reference

title

Clinical implications of new drugs for lowering plasma cholesterol concentrations (English)

1 reference

15 August 2017

Illingworth DR

1

1 reference

15 August 2017

1 February 1991

1 reference

15 August 2017

1 reference

15 August 2017

41

1 reference

15 August 2017

151-160

1 reference

15 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199141020-00001

15 August 2017

0 references

cites work

Cholesterol synthesis inhibitors in hyperlipidaemia

1 reference

12 December 2020

Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic

1 reference

12 December 2020

Therapeutic effects of ML-236B in primary hypercholesterolemia

1 reference

12 December 2020

Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B

1 reference

12 December 2020

Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia

1 reference

12 December 2020

Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia

1 reference

12 December 2020

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

1 reference

12 December 2020

The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II

1 reference

12 December 2020

Discovery, biochemistry and biology of lovastatin

1 reference

12 December 2020

A receptor-mediated pathway for cholesterol homeostasis

1 reference

12 December 2020

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

1 reference

12 December 2020

The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia

1 reference

12 December 2020

Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study

1 reference

12 December 2020

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

12 December 2020

Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

1 reference

12 December 2020

Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia

1 reference

12 December 2020

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

12 December 2020

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

1 reference

12 December 2020

Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs

1 reference

12 December 2020

Plasma mevalonate response in lovastatin-related myopathy

1 reference

12 December 2020

Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Simvastatin (MK 733): an effective treatment for hypercholesterolemia

1 reference

12 December 2020

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

12 December 2020

The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society

1 reference

12 December 2020

Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia

1 reference

12 December 2020

HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels

1 reference

12 December 2020

Efficacy and tolerability of simvastatin (MK-733).

1 reference

12 December 2020

Lipoprotein metabolism in diabetes mellitus

1 reference

12 December 2020

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

1 reference

12 December 2020

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

1 reference

12 December 2020

The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia

1 reference

12 December 2020

Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies

1 reference

12 December 2020

Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia

1 reference

12 December 2020

Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group

1 reference

12 December 2020

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

12 December 2020

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia

1 reference

12 December 2020

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

12 December 2020

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

1 reference

12 December 2020

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

1 reference

12 December 2020

Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

10.2165/00003495-199141020-00001

Identifiers

DOI

1 reference

PubMed ID

1709846

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

1709846